Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma

Journal of the Pancreas

Volumn 13, Issue 2, 2012, Pages 199-204

  Sanjay, Pandanaboyana ^a   de Figueiredo, Rodrigo S ^a   Leaver, Heather ^a   Ogston, Simon ^b   Kulli, Christoph ^a   Polignano, Francesco M ^a   Tait, Iain S ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

C reactive; Lymph nodes; Pancreatic neoplasms; Protein

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; CANCER SURVIVAL; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN TISSUE; INFLAMMATION; LEUKOCYTE COUNT; LYMPH NODE METASTASIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PANCREAS ADENOCARCINOMA; PANCREATIC DUCTAL ADENOCARCINOMA; PANCREATICODUODENECTOMY; POSTOPERATIVE LYMPH NODE RATIO; PREOPERATIVE PERIOD; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; REVIEW; THROMBOCYTE COUNT; TUMOR VOLUME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BIOPSY; C-REACTIVE PROTEIN; CARCINOMA, PANCREATIC DUCTAL; DATABASES, FACTUAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; LYMPH NODES; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; PROGNOSIS;

EID: 84858629513     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49.
2. Office of National Statistics. title typejournalCancer survival rates, Cancer Survival: England and Wales/title. Newport, South Wales, United Kingdom: 03 January, 2005. (http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-252716).
3. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003;27:324-9.
4. Benassi G, Mastrorilli M, Quarto G, et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol 2000;73:212-8.
5. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997;226:248-60.
6. Tingsted B, Johansson P, Andersson A, Andersson R. Predictive factors in pancreatic ductal adenocarcinoma: Role of the inflammatory response. Scandinavian Journal of Gastroenterology. 2007, Vol. 42, No. 6, Pages 754-759.
7. Pine JK, Fusai KG, Young R, Sharma D, Davidson BR, Menon KV, Rahman SH. Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 2009;35: 605-610. PMID: 19128923
8. Clark EJ, Connor S, Taylor MA, Madhavan KK, Garden OJ, Parks RW. Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma. HPB, 2007; 9: 456-460
9. Smith RA, Bosonnet L, Raraty R, Sutton R, Neoptolemos JP, Campbell F, Ghaneh P. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2009; 197, 466-472.
10. Garcea G, Ladwa N, Neal CP, Metcalfe MS, Dennison AR, Berry DP. Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg. 2011 Apr;35(4):868-72.
11. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg. 2010 Aug;200(2):197-203.
12. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005 Jul;138(1):8-13
13. Greer RJ, Brennan MF. Resection of pancreatic adenocarcinoma:prognostic indicators for survival. Am J Surg 1993;195:68-73.
14. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomisedcontrolled trial evaluating survival, morbidity and mortality. Ann Surg 2002;236:355-68.
15. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. BrJ Surg 2006;93:1232-7. [PMID 16804874
16. Kau SY, Shyr YM, Su CH, et al. Diagnostic and prognostic values of CA19-9 and CEA in periampullary cancers. J Am Coll Surg 1999; 188:415-20.
17. Ali AA, McMillan DC, Matalka II, McNicol AM, McArdle CS. Tumour T-lymphocyte subset infiltration and tumour recurrence following curative resection for colorectal cancer. Eur J Surg Oncol 2004;30:292-5.
18. Canna K, McArdle PA, McMillan DC, et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 2005;92:651-4.
19. Artinyan A, Anaya DA, McKenzie S, Ellenhorn JD, Kim J. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer 2011;15:2044-9.
20. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a populationbased, linked database analysis of 396 patients. Ann Surg 2003;237:74-85.
21. Pawlik TM, Abdalla EK, Barnett CC, Ahmad SA, Cleary KR, Vauthey JN, et al. Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg 2005;140:589-91.
22. Kennedy EP, Yeo CJ. Pancreaticoduodenectomy with extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. Surg Oncol Clin N Am. 2007 Jan;16(1):157-76 23.
23. Vaccaro CA, Im V, Rossi GL, Quintana GO, Benati ML, Perez de Arenaza D, Bonadeo FA. Lymph node ratio as prognosis factor for colon cancer treated by colorectal surgeons. Dis Colon Rectum. 2009 Jul;52(7):1244-50.
24. Huang C, Lin J, Zheng C, Li P, Xie J, Lin B, Wang J. Prognostic impact of metastatic lymph node ratio on gastric cancer after curative distal gastrectomy. World J Gastroenterol 2010 April 28; 16(16): 2055-2060
25. Berger AC, Watson JC, Ross EA, Hoffman JP. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004;70:235-40
26. Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009 Jul;13(7):1337-44.
27. Smith RA, Bosonnet L, Ghaneh P, Raraty M, Sutton R, Campbell F, Neoptolemos JP. Preoperative CA 19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg. 2008; 25(3):226-32.
28. Partelli S, Fernandez-Del Castillo C, Bassi C, Mantovani W, Thayer SP, Crippa S, et al. Invasive intraductal papillary mucinous carcinomas of the pancreas: predictors of survival and the role of lymph node ratio. Ann Surg. 2010 Mar;251(3):477-82. [PMID 20142730
29. Bhatti I, Peacock O, Awan AK, Semeraro D, Larvin M, Hall RI. Lymph node ratio versus number of affected lymph nodes as predictors of survival for resected pancreatic adenocarcinoma. World J Surg. 2010 Apr;34(4):768-75. [PMID 20122680
30. The Royal College of Pathologists of UK. Dataset for the histopathological reporting of carcinomas of the pancreas, ampulla of Vater and common bile duct. May 2010. http://www.rcpath.org/resources/pdf/datasethistopathologicalreportingcarcinomasmay10.pdf
31. Nagai S, Fujii T, Kodera Y, Kanda M, Sahin TT, Kanzaki A, et al. Recurrence pattern and prognosis of pancreatic cancer after pancreatic fistula. Ann Surg Oncol. 2011 Aug;18(8):2329-37. PMID: 21327822
32. Li J, Yee Merl M, Chabot J, Saif MW. Updates of Adjuvant Therapy in Pancreatic Cancer: Where Are We and Where Are We Going? JOP. J Pancreas (Online) 2010 Jul 5; 11(4):310-312.
33. Sanjay P, Leaver H, Polignano FC, Kulli C, Tait I. Preoperative C-reactive protein and lymph node ratio are important predictors of survival for pancreatic ductal adenocarcinoma. HPB 2010; 12(S1):223.